Loading
Nanexa AB Stock: price and insider trades · Sweden
Nanexa AB: what insiders have been doing
Insider filings for Nanexa AB are scarce in the Finansinspektionen feed, the latest one published on 29 September 2026. This page will fill in as new trades are disclosed. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€28,639
1 ops. · all time
Who traded when
BuySaleCecilia Danckwardt-Lillieström1 sale
Fundamental score
Ranked 19,291 of 24,148 companies
31.0
score / 100
Value30
Quality32
FCF yld-1.4%
Earn yld-0.6%
EV/EBITDA·
ROE-22%
Gross mgn·
Net mgn-32%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
SEK 10.20
Analyst consensus
Income statement
RevenueSEK 36.1M
Gross profitSEK 55.9M155% margin
EBITDASEK 4.2M12% margin
Net income-SEK 11.4M-72.5% margin
Valuation
P/Book14.7x
Beta1.38
Balance sheet & cash
Market capSEK 1.9B
Total debtSEK 2.2M
Free Cash Flow-SEK 26.2M
Debt / Equity1%
Profitability & ownership
ROE-22.0%
ROA-9.9%
% insiders27.2%
% institutions7.3%
Last declaration on 29 September 2026
Declarations1 total
25,000 shares@ SEK 13.00100.0% of flowAktieISIN SE0007074166FI:csv-0c294ddb85ab47d7eb9d
1 of 1 declaration
About Nanexa AB
Nanexa AB is a Swedish company listed on the XSTO market, specializing in the development of drug delivery technologies. It focuses on enhancing treatment efficacy through innovative methods.
